Drug Trial Radar · NCT06281678
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
Apr 8, 2024
Primary completion
Mar 1, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Renal Cell Cancer
Interventions
IBI363Drug
IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: up to 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco (UCSF)
San Francisco, California · Recruiting
Ocala Oncology Center
Ocala, Florida · Recruiting
BRCR Medical Center
Plantation, Florida · Recruiting
University of Kansas Medical Center (KUMC)
Fairway, Kansas · Recruiting
Michigan Hematology & Oncology Consultants - MedOnc Dearborn
Dearborn, Michigan · Recruiting
Michigan Hematology & Oncology Consultants - MedOnc Troy
Troy, Michigan · Recruiting
MD Anderson Cancer Center-University of Texas
Houston, Texas · Recruiting
Oncology Consultants P.A.
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.